Duncan Bucknell
Strategic Intellectual Property
Here’s a brief round up of practical things to remember from recent Australian Federal Court IP decisions. (There’s no real legal analysis here, sorry – this one is for business readers,...
Another Repatha instalment, this time the UPC (Unified Patents Court) in Europe issued it’s first decision on infringement of second medical use claims. Regeneron’s EP 3536712 patent (licensed to Sanofi) found...
“‘The technology is moving so fast and we’re so small, we don’t need a patent, we just need to move fast.” Wrong. Every small tech company is going to want to...
In fairly big news for patent litigants in the US, the Federal Circuit recently clarified that you can rely on prior art in the patent litigation, even if you have relied...
US Copyright Office released a controversial report on AI impact on copyright and then one day later Trump fired the Director, Shira Perlmutter. A key finding of the report was that...
The global dispute between Amgen and Sanofi over patent claims to Amgen’s drug Repatha® (evoloumab) saw another chapter close on 24 April. In this installment, the Australian Federal Court dismissed Sanofi’s...
Trending in intellectual property at the moment: Apple ordered to pay US $502m plus compound interest to non practicing entity Optis in FRAND patent infringement appeal to UK Court of Appeal....
Here’s a quick update on recent and important IP issues. You still need to clear the way in UK pharma patent cases. Loss of first mover advantage still holds great weight....
A self represented litigant had applied for a trade mark for “BYRON BAY BEACHFRONT APARTMENTS” which was rejected. He appealed to the Federal Court, did not fully understand the process and...
Additional Damages are fairly unusual, but can be awarded in IP Litigation based on the flagrancy of infringement, the conduct of the defendant and other matters. In a Design Infringement case...
You must be logged in to post a comment.